Research
Open Access
The impact of OHIP+ pharmacare on use and costs of public drug plans among children and youth in Ontario: a time-series analysis
Benard N. Miregwa, Anne Holbrook, Michael R. Law, John N. Lavis, Lehana Thabane, Lisa Dolovich and Michael G. Wilson
September 27, 2022 10 (3) E848-E855; DOI: https://doi.org/10.9778/cmajo.20210295
Benard N. Miregwa
Health Policy PhD Program (Miregwa), and Division of Clinical Pharmacology & Toxicology (Holbrook), and Department of Health Evidence and Impact (Holbrook, Lavis, Thabane, Dolovich, Wilson), McMaster University, Hamilton, Ont.; Centre for Health Services and Policy Research (Law), School of Population and Public Health, University of British Columbia, Vancouver, BC; McMaster Health Forum (Lavis, Wilson), McMaster University, Hamilton, Ont.; Leslie Dan Faculty of Pharmacy (Dolovich), University of Toronto, Toronto, Ont.; Centre for Health Economics and Policy Analysis (Wilson), McMaster University, Hamilton, Ont.
MSc MPHAnne Holbrook
Health Policy PhD Program (Miregwa), and Division of Clinical Pharmacology & Toxicology (Holbrook), and Department of Health Evidence and Impact (Holbrook, Lavis, Thabane, Dolovich, Wilson), McMaster University, Hamilton, Ont.; Centre for Health Services and Policy Research (Law), School of Population and Public Health, University of British Columbia, Vancouver, BC; McMaster Health Forum (Lavis, Wilson), McMaster University, Hamilton, Ont.; Leslie Dan Faculty of Pharmacy (Dolovich), University of Toronto, Toronto, Ont.; Centre for Health Economics and Policy Analysis (Wilson), McMaster University, Hamilton, Ont.
MD PharmDMichael R. Law
Health Policy PhD Program (Miregwa), and Division of Clinical Pharmacology & Toxicology (Holbrook), and Department of Health Evidence and Impact (Holbrook, Lavis, Thabane, Dolovich, Wilson), McMaster University, Hamilton, Ont.; Centre for Health Services and Policy Research (Law), School of Population and Public Health, University of British Columbia, Vancouver, BC; McMaster Health Forum (Lavis, Wilson), McMaster University, Hamilton, Ont.; Leslie Dan Faculty of Pharmacy (Dolovich), University of Toronto, Toronto, Ont.; Centre for Health Economics and Policy Analysis (Wilson), McMaster University, Hamilton, Ont.
PhDJohn N. Lavis
Health Policy PhD Program (Miregwa), and Division of Clinical Pharmacology & Toxicology (Holbrook), and Department of Health Evidence and Impact (Holbrook, Lavis, Thabane, Dolovich, Wilson), McMaster University, Hamilton, Ont.; Centre for Health Services and Policy Research (Law), School of Population and Public Health, University of British Columbia, Vancouver, BC; McMaster Health Forum (Lavis, Wilson), McMaster University, Hamilton, Ont.; Leslie Dan Faculty of Pharmacy (Dolovich), University of Toronto, Toronto, Ont.; Centre for Health Economics and Policy Analysis (Wilson), McMaster University, Hamilton, Ont.
MD PhDLehana Thabane
Health Policy PhD Program (Miregwa), and Division of Clinical Pharmacology & Toxicology (Holbrook), and Department of Health Evidence and Impact (Holbrook, Lavis, Thabane, Dolovich, Wilson), McMaster University, Hamilton, Ont.; Centre for Health Services and Policy Research (Law), School of Population and Public Health, University of British Columbia, Vancouver, BC; McMaster Health Forum (Lavis, Wilson), McMaster University, Hamilton, Ont.; Leslie Dan Faculty of Pharmacy (Dolovich), University of Toronto, Toronto, Ont.; Centre for Health Economics and Policy Analysis (Wilson), McMaster University, Hamilton, Ont.
PhDLisa Dolovich
Health Policy PhD Program (Miregwa), and Division of Clinical Pharmacology & Toxicology (Holbrook), and Department of Health Evidence and Impact (Holbrook, Lavis, Thabane, Dolovich, Wilson), McMaster University, Hamilton, Ont.; Centre for Health Services and Policy Research (Law), School of Population and Public Health, University of British Columbia, Vancouver, BC; McMaster Health Forum (Lavis, Wilson), McMaster University, Hamilton, Ont.; Leslie Dan Faculty of Pharmacy (Dolovich), University of Toronto, Toronto, Ont.; Centre for Health Economics and Policy Analysis (Wilson), McMaster University, Hamilton, Ont.
MSc PharmDMichael G. Wilson
Health Policy PhD Program (Miregwa), and Division of Clinical Pharmacology & Toxicology (Holbrook), and Department of Health Evidence and Impact (Holbrook, Lavis, Thabane, Dolovich, Wilson), McMaster University, Hamilton, Ont.; Centre for Health Services and Policy Research (Law), School of Population and Public Health, University of British Columbia, Vancouver, BC; McMaster Health Forum (Lavis, Wilson), McMaster University, Hamilton, Ont.; Leslie Dan Faculty of Pharmacy (Dolovich), University of Toronto, Toronto, Ont.; Centre for Health Economics and Policy Analysis (Wilson), McMaster University, Hamilton, Ont.
PhD